About Cambrex (NYSE:CBM)
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.
Industry, Sector and Symbol
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio17.7524429967427
Forward P/E Ratio19.40
Sales & Book Value
Annual Sales$534.46 million
Price / Sales3.35
Cash Flow$4.11 per share
Price / Cash13.27
Book Value$16.62 per share
Price / Book3.28
Net Income$102.45 million
Return on Equity22.42%
Return on Assets15.91%
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, February, 8th. The biotechnology company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.17. The biotechnology company earned $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.23 earnings per share. View Cambrex's Earnings History.
When will Cambrex make its next earnings announcement?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex issued an update on its FY18 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of $2.80-3.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.85. The company issued revenue guidance of $524-545 million (Down 2% to Up 2%), compared to the consensus revenue estimate of $538.50 million.
Where is Cambrex's stock going? Where will Cambrex's stock price be in 2018?
3 brokers have issued 1 year price targets for Cambrex's shares. Their predictions range from $60.00 to $60.00. On average, they expect Cambrex's share price to reach $60.00 in the next year. View Analyst Ratings for Cambrex.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Halozyme Therapeutics (HALO), Evotec (EVTCY), Puma Biotechnology (PBYI), China Biologic Products (CBPO), Amicus Therapeutics (FOLD), AnaptysBio (ANAB), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), arGEN-X BV (ARGX), Immunomedics (IMMU), Emergent Biosolutions (EBS) and Ultragenyx Pharmaceutical (RARE).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Steven Mark Klosk, President, Chief Executive Officer, Director (Age 60)
- Tom George Vadaketh, Chief Financial Officer, Executive Vice President (Age 54)
- Shawn P. Cavanagh, Chief Operating Officer, Executive Vice President (Age 50)
- Gregory P. Sargen, Executive Vice President, Corporate Development and Strategy (Age 51)
- Samantha M. Hanley, Vice President, General Counsel,Corporate Secretary (Age 39)
- James G. Farrell, Vice President and Corporate Controller (Age 50)
- Shlomo Yanai, Non-Executive Chairman of the Board (Age 64)
- Gregory B. Brown M.D., Director (Age 64)
- Rosina B. Dixon M.D., Independent Director (Age 74)
- Claes Glassell, Independent Director (Age 65)
Has Cambrex been receiving favorable news coverage?
News stories about CBM stock have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex earned a media sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Cambrex's major shareholders?
Cambrex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.70%), William Blair Investment Management LLC (7.16%), Bank of New York Mellon Corp (4.53%), Congress Asset Management Co. MA (4.52%), Brown Advisory Inc. (2.73%) and Boston Partners (2.17%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.
Which major investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kennedy Capital Management Inc., GW&K Investment Management LLC, BlackRock Inc., AlphaOne Investment Services LLC, Ranger Investment Management L.P., Penn Capital Management Co. Inc. and TrueNorth Inc.. Company insiders that have sold Cambrex company stock in the last year include Leon J Hendrix Jr, Samantha Hanley and Steven M Klosk. View Insider Buying and Selling for Cambrex.
Which major investors are buying Cambrex stock?
CBM stock was purchased by a variety of institutional investors in the last quarter, including Brown Advisory Inc., William Blair Investment Management LLC, Lazard Asset Management LLC, Boston Partners, Peregrine Capital Management LLC, Mackenzie Financial Corp, Summit Creek Advisors LLC and Two Sigma Advisers LP. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $54.50.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.84 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.07 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (CBM)MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cambrex (NYSE:CBM) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.67||2.67||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$60.00||$60.00||$62.33||$65.67|
|Price Target Upside: ||10.09% upside||9.19% upside||37.91% upside||16.64% upside|
Cambrex (NYSE:CBM) Consensus Price Target History
Cambrex (NYSE:CBM) Analyst Ratings History
(Data available from 3/20/2016 forward)
Cambrex (NYSE:CBM) Earnings History and Estimates Chart
Cambrex (NYSE CBM) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/8/2018||Q4 2017||$1.10||$1.27||$181.39 million||$182.28 million||View||N/A|
|11/7/2017||Q3 2017||$0.47||$0.55||$108.44 million||$112.60 million||View||N/A|
|8/4/2017||Q2 2017||$0.76||$0.76||$136.82 million||$134.55 million||View||N/A|
|5/4/2017||Q1 2017||$0.51||$0.68||$99.05 million||$105.01 million||View||Listen|
|2/3/2017||Q416||$1.05||$1.23||$174.53 million||$178.70 million||View||Listen|
|11/4/2016||Q3||$0.41||$0.47||$96.07 million||$99.90 million||View||Listen|
|7/28/2016||Q216||$0.59||$0.68||$114.85 million||$118.22 million||View||Listen|
|4/29/2016||Q116||$0.34||$0.50||$83.61 million||$94.74 million||View||Listen|
|2/9/2016||Q4||$0.83||$0.53||$152.94 million||$156.90 million||View||Listen|
|11/3/2015||Q3||$0.38||$0.40||$101.09 million||$92.97 million||View||Listen|
|7/30/2015||Q215||$0.44||$0.63||$110.03 million||$106.40 million||View||Listen|
|5/1/2015||Q115||$0.23||$0.29||$76.01 million||$78.20 million||View||Listen|
|2/6/2015||Q414||$0.50||$0.60||$117.90 million||$128.80 million||View||Listen|
|10/30/2014||Q314||$0.29||$0.28||$94.25 million||$81.10 million||View||Listen|
|8/1/2014||Q214||$0.28||$0.32||$92.70 million||$98.00 million||View||Listen|
|5/2/2014||Q114||$0.23||$0.05||$79.40 million||$66.20 million||View||Listen|
|2/11/2014||Q4||$0.30||$0.30||$95.25 million||$103.00 million||View||Listen|
|11/1/2013||Q313||$0.21||$0.20||$83.60 million||$78.00 million||View||Listen|
|8/1/2013||Q2 2013||$0.26||$0.10||$73.70 million||$61.60 million||View||Listen|
|5/3/2013||Q1 2013||$0.22||$0.36||$76.15 million||$74.58 million||View||Listen|
|2/6/2013||Q4 2012||$0.13||$0.26||$68.30 million||$69.93 million||View||Listen|
|11/5/2012||Q312||$0.12||$0.07||$61.00 million||$59.21 million||View||N/A|
Cambrex (NYSE:CBM) Earnings Estimates
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cambrex (NYSE:CBM)
No dividend announcements for this company have been tracked by MarketBeat.com
Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.48%
Cambrex (NYSE CBM) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/2/2017||Steven M Klosk||CEO||Sell||4,000||$54.96||$219,840.00||87,328|| |
|9/1/2017||Steven M Klosk||CEO||Sell||12,000||$51.53||$618,360.00||95,328|| |
|8/1/2017||Steven M Klosk||CEO||Sell||12,000||$61.39||$736,680.00||95,328|| |
|7/3/2017||Steven M Klosk||CEO||Sell||12,000||$59.66||$715,920.00||95,328|| |
|6/12/2017||Samantha Hanley||VP||Sell||14,000||$57.56||$805,840.00||1,500|| |
|6/6/2017||Leon J Hendrix Jr||Director||Sell||20,656||$55.95||$1,155,703.20||74,662|| |
|6/1/2017||Steven M Klosk||CEO||Sell||12,000||$54.19||$650,280.00||95,328|| |
|5/1/2017||Steven M Klosk||CEO||Sell||12,000||$58.20||$698,400.00||95,328|| |
|4/3/2017||Steven M Klosk||CEO||Sell||12,000||$54.58||$654,960.00||95,328|| |
|3/1/2017||Steven M Klosk||CEO||Sell||12,000||$56.70||$680,400.00||95,328|| |
|2/27/2017||Shawn Cavanagh||COO||Sell||19,620||$55.95||$1,097,739.00||17,658|| |
|2/16/2017||Steven M Klosk||CEO||Sell||23,822||$52.50||$1,250,655.00||94,241|| |
|2/13/2017||Steven M Klosk||CEO||Sell||63,178||$52.55||$3,320,003.90||109,062|| |
|2/7/2017||Gregory Sargen||EVP||Sell||30,000||$54.88||$1,646,400.00||50,000|| |
|2/7/2017||Shawn Cavanagh||COO||Sell||20,380||$55.12||$1,123,345.60||57,658|| |
|12/14/2016||Shawn Cavanagh||COO||Sell||30,000||$53.58||$1,607,400.00||27,658|| |
|11/11/2016||Gregory Sargen||Insider||Sell||22,500||$52.02||$1,170,450.00||27,500|| |
|7/11/2016||William B Korb||Director||Sell||3,420||$55.00||$188,100.00||23,982|| |
|6/8/2016||William B Korb||Director||Sell||4,142||$52.47||$217,330.74||24,704|| |
|6/1/2016||William B Korb||Director||Sell||8,000||$51.06||$408,480.00||25,304|| |
|5/9/2016||Steven M Klosk||CEO||Sell||14,005||$49.00||$686,245.00||147,333|| |
|5/5/2016||Steven M Klosk||CEO||Sell||16,430||$49.13||$807,205.90||136,828|| |
|5/3/2016||William B Korb||Director||Sell||8,000||$49.09||$392,720.00||32,562|| |
|3/16/2016||Steven M Klosk||CEO||Sell||19,565||$41.00||$802,165.00||152,893|| |
|3/15/2016||Louis J Grabowsky||Director||Buy||750||$40.10||$30,075.00||928|| |
|3/10/2016||William B Korb||Director||Sell||8,000||$41.38||$331,040.00||32,562|| |
|2/11/2016||Gregory Sargen||CFO||Sell||13,622||$36.16||$492,571.52||46,697|| |
|2/11/2016||Shawn Cavanagh||COO||Sell||18,342||$36.13||$662,696.46||17,658|| |
|2/11/2016||Steven M. Klosk||CEO||Sell||39,542||$36.20||$1,431,420.40||133,328|| |
|12/15/2015||Leon J. Hendrix, Jr.||Director||Sell||7,000||$51.34||$359,380.00||71,211|| |
|12/11/2015||Peter G. Tombros||Director||Sell||31,236||$51.37||$1,604,593.32||21,520|| |
|11/30/2015||Ilan Kaufthal||Director||Sell||52,315||$54.32||$2,841,750.80||60,000|| |
|11/13/2015||Gregory Sargen||CFO||Sell||28,750||$49.14||$1,412,775.00||33,319|| |
|11/6/2015||Samantha Hanley||VP||Sell||15,000||$52.03||$780,450.00|| |
|8/27/2015||William B. Korb||Director||Sell||3,600||$48.00||$172,800.00||46,562|| |
|5/21/2015||Ilan Kaufthal||Director||Sell||50,000||$41.31||$2,065,500.00|| |
|5/11/2015||Gregory Sargen||CFO||Sell||25,000||$38.44||$961,000.00|| |
|2/12/2015||Aldo Magnini||Director||Sell||7,500||$32.75||$245,625.00|| |
|2/12/2015||Gregory Sargen||CFO||Sell||25,000||$32.64||$816,000.00|| |
|2/10/2015||Steven M Klosk||CEO||Sell||45,000||$30.32||$1,364,400.00|| |
|9/11/2014||Shawn Cavanagh||COO||Sell||56,251||$22.56||$1,269,022.56|| |
|9/3/2014||Steven M Klosk||CEO||Sell||126,257||$22.01||$2,778,916.57|| |
|9/2/2014||William M Haskel||SVP||Sell||9,400||$21.94||$206,236.00|| |
|8/19/2014||Steven M Klosk||CEO||Sell||4,702||$22.00||$103,444.00|| |
|8/7/2014||Steven M Klosk||CEO||Sell||1,200||$22.52||$27,024.00|| |
|8/7/2014||William M Haskel||SVP||Sell||28,100||$22.50||$632,250.00|| |
|8/5/2014||Gregory Sargen||CFO||Sell||50,000||$22.34||$1,117,000.00|| |
|2/28/2014||Leon Hendrix, Jr.||Director||Sell||23,000||$20.09||$462,070.00||92,993|| |
|2/20/2014||Aldo Magnini||Director||Sell||6,000||$22.10||$132,600.00|| |
|12/5/2013||Paolo Russolo||Insider||Sell||35,000||$18.40||$644,000.00||67,085|| |
|11/11/2013||Gregory Sargen||CFO||Sell||20,000||$18.92||$378,400.00||33,319|| |
|11/11/2013||John Miller||Director||Sell||2,000||$19.21||$38,420.00||35,306|| |
|5/24/2013||Paolo Russolo||Insider||Sell||32,903||$12.53||$412,274.59|| |
|5/16/2013||Leon J Hendrix Jr||Director||Sell||1,120||$13.40||$15,008.00|| |
Cambrex (NYSE CBM) News Headlines
Cambrex (NYSE:CBM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement
Cambrex (NYSE CBM) Stock Chart for Tuesday, March, 20, 2018